Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial - le Roux, C W; Lucas, K J; Startseva, E (Lancet Diabetes Endocrinol, 2024)